Description
release form
Capsules
Packing
100 pcs.
Pharmacological action of
Mycophenolate Mofetil-T has an immunosuppressive effect. Selectively inhibits inosine monophosphate dehydrogenase and inhibits the synthesis of guanosine nucleotoid. It has a pronounced cytostatic effect on lymphocytes, inhibits their proliferation, and inhibits the formation of antibodies by B-lymphocytes. When taken orally, it is rapidly absorbed and completely hydrolyzed, forming mycophenolic acid. It is excreted mainly by the kidneys. In combination with azathioprine and cyclosporine, as well as with the induction course of antithymocytic globulin, reduces the frequency of adverse outcomes in the first 6 months after transplantation.
Indications
Prevention of rejection reactions and treatment of allogeneic renal transplant rejection (in combination with cyclosporin A and glucocorticoids).
Contraindications
Hypersensitivity, exacerbation of gastric and duodenal ulcer and other gastrointestinal diseases, pregnancy, breast-feeding, children.
Special instructions
It is necessary to take into account the possibility of increasing the risk of developing lymphoproliferative processes, regularly monitoring the composition of peripheral blood, and with a decrease in the number of neutrophils, a dose reduction or a break in treatment (and appropriate therapy) is indicated. In case of a decrease in glomerular filtration rate below, it is not recommended to use more than 2 times a day. For more information, see the instructions for medical use of the drug.
Composition
1 capsule contains:
Active substances: mycophenolate mofetil 250 mg
Excipients: microcrystalline cellulose 0.065 g, povidone K90 0.014 g, croscarmellose sodium 0.0175 g, magnesium stearate 0.005 g iron oxide red 0.02 g srd % iron oxide red oxide – 0.0224%, iron oxide yellow oxide 0.4343%, titanium dioxide 0.5265%, gelatin up to 100%.
Composition of capsule cap: iron oxide black 0.7%, iron oxide red 0.07%, iron oxide yellow 0.5%, titanium dioxide 0.667%, gelatin up to 100%.
Dosage and administration
Used as part of combination therapy with cyclosporine and corticosteroids. To prevent the transplant rejection reaction, the first dose of mycophenolate mofetil is taken during the first 3 days after surgery. When administered, the recommended dose is 2 g per day, the frequency of administration – 2 times a day. For the treatment of rejection reactions – 3 g per day.
Side effects
Nausea, vomiting, diarrhea, constipation, leukopenia or leukocytosis, anemia, thrombocytopenia, increased incidence of infectious and septic complications headaches, insomnia, tremor, fever, asthenia, lumbago, hypertension, cough, hypertension, cough , oropharyngeal candidiasis, hematuria, tubular necrosis, impotence, acne, hyper- or hypokalemia, hyperglycemia, hypophosphatemia, hypercholesterolemia, allergic reactions, rash, pruritus.
Drug Interactions
Probenecid and other drugs affecting tubular secretion increase the plasma concentration of mycophenolic acid. Antacids containing magnesium and aluminum hydroxides reduce absorption. Drugs that alter the flora of the gastrointestinal tract may interfere with enterohepatic circulation. Reduces the effectiveness of oral contraception. Azathioprine increases the risk of developing lymphomas, especially the skin.
Overdose
Symptoms: Increased incidence of gastrointestinal and hematological (in particular neutropenia) side effects.
Treatment: Dose reduction or withdrawal of the drug. To accelerate excretion, the appointment of bile acid sequestrants is possible. Small amounts of glucuronide can be removed by hemodialysis (mycophenolic acid is not dialysable).
Storage Conditions
In a dry, dark place at a temperature not exceeding 30 ° C.
Keep out of the reach and sight of children.
Shelf life
2 years
Deystvuyushtee substance
mycophenolic mofetil
Terms and conditions
prescription
dosage form
capsules
Possible product names
Mycophenolate Mofetil-TL caps 250mg polymer bank / N100
Mycophenolate Mofetil-T capsules 250 mg, 100 pcs.
